Huahai Pharma receives approval for nimodipine tablets

Zhejiang Huahai Pharmaceutical Co., Ltd. (SSE: 600521) announced that it has received approval from the National Medical Products Administration (NMPA) for its Nimodipine tablets. The approved drug includes specifications for 5mg and 10mg dosages and is categorized as a Class 3 chemical drug. Nimodipine tablets are indicated for improving cognitive function affected by cerebral infarction sequelae and are applicable for vascular dementia, particularly in early treatment stages. While Nimodipine tablets were originally developed by Pfizer and launched in Italy in 1972, Huahai will now be able to produce and market the drug within China. The company has invested approximately CNY 8.99 million in the research and development of this drug. Huahai Pharma stated that this approval will enrich its product offerings and enhance its market competitiveness. According to market data, Nimodipine's market potential in China is significant, with 2024 sales estimated at around CNY 555 million.